Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Shanghai-headquartered Hutchison MediPharma has frozen development of a cancer drug after Phase II clinical trials conducted in China produced inconclusive data on the efficacy of the medicine, according to company executives

You may also be interested in...



Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China

SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6

Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China

SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6

China's Hutchison MediPharma Phase IIb Trials In Ulcerative Colitis Meet Primary, Secondary Endpoints

SHANGHAI - Chinese biotech Hutchison MediPharma announced Nov. 5 that its Phase IIb global clinical trial of lead candidate HMPL-004 in patients with ulcerative colitis, a form of inflammatory bowel disease, met primary and key secondary endpoints

Related Content

Latest News
UsernamePublicRestriction

Register

SC066821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel